News & Media
About Abiomed and Impella® Heart Pumps
Based in Danvers, Massachusetts, USA, Abiomed, Inc. (NASDAQ: ABMD) is a leading provider of medical devices that provide circulatory and respiratory support. Our cardiac products are designed to enable the heart to rest and recover by improving blood flow and/or performing the pumping of the heart. Our easy-to-use respiratory product is designed to oxygenate the blood, while promoting mobility.
Impella heart pumps are the only U.S. Food and Drug Administration-approved percutaneous heart pump technology indicated for patients with severe coronary artery disease requiring high-risk PCI or treatment of AMI cardiogenic shock. Impella has the unique ability to enable your heart to recover, allowing patients to return home from the hospital with their native hearts.
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
May 19, 2022
World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
April 26, 2022